XML 41 R10.htm IDEA: XBRL DOCUMENT v3.20.1
RESTRUCTURING
 12 Months Ended
Mar. 28, 2020
Restructuring and Related Activities [Abstract]  
RESTRUCTURING RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.

In July 2019, the Board of Directors of the Company approved a new Operational Excellence Program (the "2020 Program") and delegated authority to the Company's management to determine the detail of the initiatives that will comprise the program. The 2020 Program is designed to improve operational performance and reduce cost principally in our manufacturing and supply chain operations. The Company estimates that it will incur aggregate charges between $60 million and $70 million in connection with the 2020 Program. These charges, the majority of which will result in cash outlays, including severance and other employee costs, will be incurred as the specific actions required to execute these initiatives are identified and approved and are expected to be substantially completed by the end of fiscal 2023. During fiscal 2020, the Company incurred $11.9 million of restructuring and turnaround costs under this program.

During fiscal 2018, the Company launched a Complexity Reduction Initiative (the "2018 Program"), a company-wide restructuring program designed to improve operational performance and reduce cost, freeing up resources to invest in accelerated growth. During fiscal 2020, 2019 and 2018 the Company incurred $7.9 million, $13.7 million and $36.6 million of restructuring and turnaround costs under this program, respectively. Total cumulative charges under this program are $58.2 million as of March 28, 2020. The 2018 Program is substantially complete.

During fiscal 2017, the Company launched a restructuring program (the "2017 Program") designed to reposition its organization and improve its cost structure. The Company did not incur any charges under this program during fiscal 2020 and 2019. During fiscal 2018, the Company incurred $7.2 million of restructuring and turnaround charges under this program, respectively. The 2017 Program is substantially complete.

The following table summarizes the activity for restructuring reserves related to the 2020 Program and the 2018 and Prior Programs for the fiscal years ended March 28, 2020, March 30, 2019 and March 31, 2018, substantially all of which relates to employee severance and other employee costs:
(In thousands)
2020 Program
 
2018 and Prior Programs
 
Total
Balance at April 1, 2017
$
—

 
$
7,468

 
$
7,468

Costs incurred, net of reversals
—

 
30,529

 
30,529

Payments
—

 
(8,260
)
 
(8,260
)
Non-cash adjustments
—

 
(1,202
)
 
(1,202
)
Balance at March 31, 2018
$
—

 
$
28,535

 
$
28,535

Costs incurred, net of reversals
—

 
395

 
395

Payments
—

 
(21,392
)
 
(21,392
)
Non-cash adjustments
—

 
(59
)
 
(59
)
Balance at March 30, 2019
$
—

 
$
7,479

 
$
7,479

Costs incurred, net of reversals
2,234

 
1,357

 
3,591

Payments
(1,098
)
 
(7,177
)
 
(8,275
)
Non-cash adjustments
—

 
(147
)
 
(147
)
Balance at March 28, 2020
$
1,136

 
$
1,512

 
$
2,648



The following presents the restructuring costs by line item during fiscal 2020, 2019 and 2018 within our accompanying consolidated statements of income and comprehensive income:
(In thousands)
2020
 
2019
 
2018
Cost of goods sold
$
1,082

 
$
—

 
$
1

Research and development
532

 
741

 
4,671

Selling, general and administrative expenses
1,977

 
(346
)
 
25,857

Total
$
3,591

 
$
395

 
$
30,529



As of March 28, 2020, the Company had a restructuring liability of $2.6 million, of which approximately $2.2 million is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs of $16.3 million, $13.2 million and $13.6 million in fiscal 2020, 2019 and 2018, respectively, that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as turnaround costs. These costs consist primarily of expenditures directly related to the restructuring actions and include program management costs associated with the implementation of outsourcing initiatives and recent accounting standards.

The following presents the turnaround costs by line item during fiscal 2020, 2019 and 2018 within our accompanying consolidated statements of income and comprehensive income:
(In thousands)
2020
 
2019
 
2018
Cost of goods sold
$
2,227

 
$
1,305

 
$
716

Research and development
354

 
—

 
4

Selling, general and administrative expenses
13,706

 
11,923

 
12,876

Total
$
16,287

 
$
13,228

 
$
13,596


The tables below present restructuring and turnaround costs by reportable segment:
Restructuring costs
 
 
 
 
 
(In thousands)
2020
 
2019
 
2018
Plasma
$
544

 
$
(67
)
 
$
3,649

Blood Center
(5
)
 
164

 
3,838

Hospital
845

 
828

 
3,853

Corporate
2,207

 
(530
)
 
19,189

Total
$
3,591

 
$
395

 
$
30,529

 
 
 
 
 
 
Turnaround costs
 
 
 
 
 
(In thousands)
2020
 
2019
 
2018
Plasma
$
820

 
$
174

 
$
973

Blood Center
320

 
145

 
35

Hospital
—

 
(270
)
 
(30
)
Corporate
15,147

 
13,179

 
12,618

Total
$
16,287

 
$
13,228

 
$
13,596

 
 
 
 
 
 
Total restructuring and turnaround
$
19,878

 
$
13,623

 
$
44,125